Skip to main content
Swing Capital

J B Chemicals & Pharmaceuticals Ltd

NSE: JBCHEPHARM BSE: 506943Pharma

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

₹2,135
52W: ₹1603 — ₹2225
PE 49.4 · Book ₹251 · +751% vs book
Market Cap₹34,278 Cr
Stock P/E49.4Price to Earnings
ROCE25.2%Return on Capital
ROE18.7%Return on Equity
Div. Yield0.72%Face Value ₹1

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 31.4%
  • +Promoter holding has increased by 1.25% over last quarter.

Weaknesses

  • −Stock is trading at 8.35 times its book value
  • −Promoter holding has decreased over last 3 years: -5.13%
  • −Working capital days have increased from 108 days to 197 days

Shareholding Pattern

Promoters48.8%
FIIs16.33%
DIIs21.38%
Public13.48%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters53.77%53.74%▼0.053.66%▼0.147.84%▼5.847.73%▼0.147.56%▼0.247.55%▼0.048.8%▲1.3
FIIs12.17%13.63%▲1.514.64%▲1.018.3%▲3.717.77%▼0.515.31%▼2.514.88%▼0.416.33%▲1.4
DIIs17.61%16.81%▼0.816.4%▼0.418.71%▲2.319.62%▲0.922.83%▲3.223.35%▲0.521.38%▼2.0
Public16.42%15.8%▼0.615.29%▼0.515.13%▼0.214.87%▼0.314.31%▼0.614.21%▼0.113.48%▼0.7

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales8008099529569149011,0401,023991836
Expenses585614679688668670747724721642
Operating Profit215195273268245231293298270195
OPM %27%24%29%28%27%26%28%29%27%23%
Net Profit12812617317315615019820017997
EPS ₹8.258.1111.1611.1510.059.6212.6812.811.446.01

AI Insights

Revenue Trend

Mar 2026 revenue at ₹3,890Cr, up 4.5% YoY. OPM at 27%.

Debt Position

Borrowings at ₹3Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.

Capex Cycle

CWIP at ₹61Cr (3% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 21.38% (+2.73pp change). FIIs: 16.33% (+6.80pp change). Promoters hold 48.8%.

Margin & Efficiency

ROCE improving from 14% (Mar 2015) to 25% (Mar 2026). Working capital days: 197.

Valuation

PE 49.4x with 25.2% ROCE. Price is 751% above book value of ₹251. Dividend yield: 0.72%.

Recent Announcements